1000000
100000000
50000
10000000
5000
2.65
2155000
154000
1000000
4000000
16878180
2
5.63
2017-03-28
1
9.00
46378
5.63
2016-05-02
1333361
13130000
16299627
7395908
1562500
5.58
3552840
1315137
1562500
50000000
0.001
5000000
16299627
1493000
36000
79000
10000
91394000
285000
83000
5000
-3089000
632000
241000
1129000
1498000
16000
5225000
6000
26000
6000
5225000
5099000
95131000
4962000
88000
5187000
3.74
0.01
8001000
1000000
10
20000000
-95131000
91394000
215
2105000
1562500
632000
16299627
16000
2100000
3005000
900000
1706000
2000
215
215
1000
2105000
5110000
2182000
2100000
2100000
2100000
3005000
4200000
4200000
900000
900000
900000
1706000
1800000
1800000
100000000
6397000
16060853
7424241
1562500
5.66
3539961
1562500
50000000
0.001
5000000
16060853
1638000
42000
80000
10000
80535000
397000
109000
6000
1165000
632000
1161000
1644000
16000
9561000
6000
30000
8000
9561000
9364000
80018000
153000
9517000
3.71
0.01
8001000
1000000
20000000
-80018000
80535000
220
2154000
1562500
632000
16060853
16000
2100000
2900000
900000
1698000
583000
220
220
1000
2154000
2100000
2100000
2100000
2900000
900000
900000
900000
1698000
GALT
GALECTIN THERAPEUTICS INC
false
Smaller Reporting Company
2013
10-Q
2013-06-30
0001133416
--12-31
Q2
6.40
<div>
<table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%">
<tr>
<td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>1.</b></font></td>
<td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Basis of
Presentation</b></font></td>
</tr>
</table>
<p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px">
<font style="FONT-FAMILY: Times New Roman" size="2">Galectin
<font style="FONT-FAMILY: 'Times New Roman'" size="2"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Therapeutics Inc. (the
“Company”) is a development-stage company that is
applying its leadership in galectin science and drug development to
create new therapies for fibrotic disease and cancer. These
therapeutic candidates are based on the Company’s targeting
of galectin proteins which are key mediators of biologic and
pathologic function. These compounds also may have application for
drugs to treat other diseases and chronic health
conditions.</font></font></font></p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12px; TEXT-INDENT: 8%; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
<font style="FONT-FAMILY: Times New Roman" size="2"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><font style="FONT-FAMILY: 'Times New Roman'" size="2">The unaudited condensed
consolidated financial statements as reported in this Quarterly
Report on Form 10-Q reflect all adjustments which are, in the
opinion of management, necessary to present fairly the financial
position of the Company as of June 30, 2013 and the results of
its operations for the three and six months ended June 30,
2013 and 2012 and the cumulative period from inception (July 10,
2000) through June 30, 2013 and its cash flows for the six
months ended June 30, 2013 and 2012, and for the cumulative
period from inception (July 10, 2000) to June 30, 2013. Such
adjustments, other than nonrecurring adjustments that have been
separately disclosed, are of a normal, recurring nature. The
Company considers events or transactions that occur after the
balance sheet date but before the financial statements are issued
to provide additional evidence relative to certain estimates or to
identify matters that require additional disclosure. Subsequent
events have been evaluated through the date these financial
statements are available to be issued. The results for interim
periods are not necessarily indicative of results which may be
expected for any other interim period or for the full year. The
unaudited condensed consolidated financial statements of the
Company should be read in conjunction with its Annual Report on
Form 10-K for the year ended December 31,
2012.</font></font></font></p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12px; TEXT-INDENT: 8%; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
<font style="FONT-FAMILY: Times New Roman" size="2"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><font style="FONT-FAMILY: 'Times New Roman'" size="2">The Company has operated
at a loss since its inception and has had no significant revenues.
The Company anticipates that losses will continue for the
foreseeable future as is develops its therapeutic candidates. At
June 30, 2013, the Company had $5,099,000 of unrestricted cash
and cash equivalents available to fund future operations.
Subsequent to June 30, 2013, the Company received $2,429,923
from the exercise of warrants for 578,553 shares of common stock.
The Company believes that with the cash on hand at June 30,
2013 and the cash received subsequent to quarter end, there is
sufficient cash to fund operations through the first quarter of
2014. The Company’s ability to fund operations after its
current cash resources are exhausted depends on its ability to
obtain additional financing or achieve profitable operations, as to
which no assurances can be given. The Company has developed several
plans, including cost containment efforts and potential strategic
alternatives in the event that such financing cannot be realized by
the Company. Accordingly, based on the forecasts and estimates
underlying the Company’s current operating plan, the
financial statements do not currently include any adjustments that
might be necessary if the Company is unable to continue as a going
concern.</font></font></font></p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12px; TEXT-INDENT: 8%; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
<font style="FONT-FAMILY: Times New Roman" size="2"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><font style="FONT-FAMILY: 'Times New Roman'" size="2">As shown in the condensed
consolidated financial statements, the Company incurred cumulative
net losses applicable to common stockholders of $95.4 million for
the cumulative period from inception (July 10, 2000) through
June 30, 2013. The Company’s net losses have resulted
principally from costs associated with (i) research and
development expenses, including clinical trial costs,
(ii) general and administrative activities and (iii) the
Company’s financing transactions including interest, dividend
payments, and the costs related to fair value accounting for the
Company’s convertible debt instruments. As a result of
planned expenditures for future research, discovery, development
and commercialization activities and potential legal cost to
protect its intellectual property, the Company expects to incur
additional losses and use additional cash in its operations for the
foreseeable future. Through June 30, 2013, the Company had
raised a net total of $68.8 million in capital through sale and
issuance of common stock, common stock purchase warrants,
convertible preferred stock and debt securities in public and
private offerings. From inception (July 10, 2000) through
June 30, 2013, the Company used cash of $62.9 million in its
operations.</font></font></font></p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12px; TEXT-INDENT: 8%; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
<font style="FONT-FAMILY: Times New Roman" size="2"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><font style="FONT-FAMILY: 'Times New Roman'" size="2">The Company was founded
in July 2000, was incorporated in the State of Nevada in January
2001 under the name “Pro-Pharmaceuticals, Inc.,” and
changed its name to “Galectin Therapeutics Inc.” on
May 26, 2011. On March 23, 2012, the Company
began trading on The NASDAQ Capital Market under the symbol GALT.
Immediately prior to March 23, 2012, the Company was traded on
the Over-the Counter Bulletin Board (“OTCBB”) under the
symbol GALT.OB.</font></font></font></p>
<p style="TEXT-TRANSFORM: none; MARGIN-TOP: 12px; TEXT-INDENT: 8%; LETTER-SPACING: normal; FONT: medium 'Times New Roman'; WHITE-SPACE: normal; MARGIN-BOTTOM: 0px; COLOR: rgb(0,0,0); WORD-SPACING: 0px; -webkit-text-stroke-width: 0px">
<font style="FONT-FAMILY: Times New Roman" size="2"><font style="FONT-FAMILY: 'Times New Roman'" size="2"><font style="FONT-FAMILY: 'Times New Roman'" size="2">The Company is subject to
a number of risks similar to those of other development-stage
companies, including dependence on key individuals, uncertainty of
product development and generation of revenues, dependence on
outside sources of capital, risks associated with clinical trials
of products, dependence on third-party collaborators for research
operations, need for regulatory approval of products, risks
associated with protection of intellectual property, and
competition with larger, better-capitalized companies. Successful
completion of the Company’s development program and,
ultimately, the attainment of profitable operations is dependent
upon future events, including obtaining adequate financing to
fulfill its development activities and achieving a level of
revenues adequate to support the Company’s cost structure.
There are no assurances that the Company will be able to obtain
additional financing on favorable terms, or at all, or successfully
market its products.</font></font></font></p>
</div>
<div>
<p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px">
<font style="FONT-FAMILY: Times New Roman" size="2">Dilutive shares
which could exist pursuant to the exercise of outstanding stock
instruments and which were not included in the calculation because
their affect would have been anti-dilutive are as
follows:</font></p>
<p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">
 </p>
<table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center">
<tr>
<td width="74%"></td>
<td valign="bottom" width="3%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="3%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1">June 30, 2013<br />
(shares)</font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1">June 30, 2012<br />
(shares)</font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Warrants to purchase shares
of common stock</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,395,908</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,424,241</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
</tr>
<tr>
<td valign="top">
<p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options to purchase shares
of common stock</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,552,840</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,291,630</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Shares of common stock
issuable upon conversion of preferred stock</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,618,772</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,627,110</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td> </td>
</tr>
<tr>
<td valign="top"></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">13,567,520</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">13,342,981</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
</tr>
</table>
</div>
0.0097
<div>
<p style="margin-top:12px;margin-bottom:0px; text-indent:8%">
<font style="font-family:Times New Roman" size="2">The following
table summarizes the stock option activity in the Company’s
equity incentive plans, including non-plan grants to Company
executives, from December 31, 2012 through June 30,
2013:</font></p>
<p style="font-size:12px;margin-top:0px;margin-bottom:0px">
 </p>
<table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE" align="center">
<tr>
<td width="72%"></td>
<td valign="bottom" width="8%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="8%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1">Shares</font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1">Weighted Average<br />
Exercise Price</font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Outstanding,
December 31, 2012</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">3,539,961</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">5.66</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Granted</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">225,426</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">3.42</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Exercised</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">(102,594</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">) </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">2.57</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Options
forfeited/cancelled</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">(109,953</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">) </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">6.40</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Outstanding, June 30,
2013</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">3,552,840</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">5.58</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
</tr>
</table>
</div>
1.16
3.42
<div>
<table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%">
<tr>
<td width="4%" valign="top" align="left"><font style="font-family:Times New Roman" size="2"><b>5.</b></font></td>
<td align="left" valign="top"><font style="font-family:Times New Roman" size="2"><b>Fair Value of Financial
Instruments</b></font></td>
</tr>
</table>
<p style="margin-top:6px;margin-bottom:0px; text-indent:8%">
<font style="font-family:Times New Roman" size="2">The Company has
certain financial assets and liabilities recorded at fair value.
Fair values determined by Level 1 inputs utilize observable data
such as quoted prices in active markets. Fair values determined by
Level 2 inputs utilize data points other than quoted prices in
active markets that are observable either directly or indirectly.
Fair values determined by Level 3 inputs utilize unobservable data
points in which there is little or no market data, which require
the reporting entity to develop its own assumptions. The carrying
amounts reflected in the consolidated balance sheets for cash
equivalents, accounts payable and accrued expenses approximates
their carrying value due to their short-term nature. Included in
cash and cash equivalents, as of June 30, 2013 and
December 31, 2012, the Company had $2,000 and $583,000,
respectively invested in money market funds which had calculated
net asset values and were therefore classified as Level 2. There
were no level 3 assets held at fair value at June 30, 2013 or
December 31, 2012.</font></p>
</div>
P5Y6M
<div>
<p style="margin-top:6px;margin-bottom:0px; text-indent:8%">
<font style="font-family:Times New Roman" size="2">Accrued expenses
consist of the following:</font></p>
<p style="font-size:12px;margin-top:0px;margin-bottom:0px">
 </p>
<table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE" align="center">
<tr>
<td width="78%"></td>
<td valign="bottom" width="6%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="6%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1">June 30,</font><br />
<font style="font-family:Times New Roman" size="1">2013</font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1">December 31,<br />
2012</font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom" colspan="6" align="center"><font style="font-family:Times New Roman" size="1">(in thousands)</font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Legal and accounting
fees</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">83</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">109</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Accrued
compensation</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">36</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">42</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Severance agreement (Note
8)</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">1,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">1,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Other</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">10</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">10</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Total</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">1,129</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">1,161</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td> </td>
</tr>
</table>
</div>
<div>
<table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%">
<tr>
<td width="4%" valign="top" align="left"><font style="font-family:Times New Roman" size="2"><b>2.</b></font></td>
<td align="left" valign="top"><font style="font-family:Times New Roman" size="2"><b>Accrued
Expenses</b></font></td>
</tr>
</table>
<p style="margin-top:6px;margin-bottom:0px; text-indent:8%">
<font style="font-family:Times New Roman" size="2">Accrued expenses
consist of the following:</font></p>
<p style="font-size:12px;margin-top:0px;margin-bottom:0px">
 </p>
<table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE" align="center">
<tr>
<td width="78%"></td>
<td valign="bottom" width="6%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="6%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1">June 30,</font><br />
<font style="font-family:Times New Roman" size="1">2013</font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1">December 31,<br />
2012</font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom" colspan="6" align="center"><font style="font-family:Times New Roman" size="1">(in thousands)</font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Legal and accounting
fees</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">83</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">109</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Accrued
compensation</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">36</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">42</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Severance agreement (Note
8)</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">1,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">1,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Other</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">10</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">10</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Total</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">1,129</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">1,161</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td> </td>
</tr>
</table>
</div>
16158000
<div>
<table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%">
<tr>
<td width="4%" valign="top" align="left"><font style="font-family:Times New Roman" size="2"><b>4.</b></font></td>
<td align="left" valign="top"><font style="font-family:Times New Roman" size="2"><b>Common Stock
Warrants</b></font></td>
</tr>
</table>
<p style="margin-top:6px;margin-bottom:0px; text-indent:8%">
<font style="font-family:Times New Roman" size="2">The following
table summarizes the common stock warrant activity from
December 31, 2012 through June 30, 2013:</font></p>
<p style="font-size:12px;margin-top:0px;margin-bottom:0px">
 </p>
<table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE" align="center">
<tr>
<td width="72%"></td>
<td valign="bottom" width="8%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="8%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1">Shares</font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1">Weighted Average<br />
Exercise Price</font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Outstanding,
December 31, 2012</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">7,424,241</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">3.71</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Granted</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">5,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">2.65</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Exercised</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">—  </font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">—  </font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Forfeited/cancelled</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">(33,333</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">) </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">3.00</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Outstanding, June 30,
2013</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">7,395,908</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">3.74</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
</tr>
</table>
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2"><i>Warrants
Modification</i></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%">
<font style="font-family:Times New Roman" size="2">On May 6,
2013, the Company modified the terms of the Class A-2 and
Class B warrants that were originally issued to the 10X Fund with
the Series B Preferred Stock offering. The Class B warrants were
modified to allow for the cashless exercise of all 4,000,000
outstanding Class B warrants. Previously, only half of the Class B
warrants allowed for cashless exercise. The Class A-2 warrants
for the purchase of 1,000,000 shares of common and all of the Class
B warrants had their exercisable life extended by an additional
five years. In exchange for these modifications, the 10X Fund
agreed to a future amendment of the Company’s Series B
certificate of designation to remove the redemption provision such
that the Series B Preferred Stock will no longer be redeemable, if
and when the Company will no longer be required to issue
Dr. Platt a promissory note as may currently be required under
the separation agreement (see Note 8). Should the Company
amend their Series B certificate of designation in the future as
described above, the Company will be required at that time evaluate
whether such amendment is to be accounted for as a modification or
an extinguishment of the Company’s Series B Preferred
Stock. The Company has accounted for the modified terms of the
Class A-2 and Class B warrants pursuant to ASC 718, Stock
Compensation, whereby the Company has recognized a charge for the
change in fair value of the warrants immediately before and
immediately after the modification. For the three and six
month period ended June 30, 2013, the Company recognized a
charge of $8,763,000 related to the extension of the 5,000,000
warrants. The following assumptions were used to value the
extension of the warrants immediately before and immediately after
the modification: a) immediately before the modification—an
expected life range of 0.77 to 2.01 years, volatility range of 77%
to 96%, risk free interest rate range of 0.11% to 0.22% and zero
dividends and; b) immediately following the modification—an
expected life range of 5.78 to 7.02 years, volatility range of 113%
to 122%, risk free interest rate range of 0.74% to 1.19% and zero
dividends.</font></p>
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2"><i>Consultant
Warrants</i></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:8%">
<font style="font-family:Times New Roman" size="2">In January 2013,
the Company entered into an agreement with a consultant that
provided for the grant of warrants for the purchase of 5,000 shares
of common stock at an exercise price of $2.65 per share. The
following assumptions were used to value the warrants: an expected
life of 3 years, volatility of 87%, risk free interest rate of
0.42% and zero dividends. The Company recognized an expense of
$7,000 related to these warrants during the six months ended
June 30, 2013.</font></p>
</div>
2.83
0.00
-4355000
<div>
<table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%">
<tr>
<td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>6.</b></font></td>
<td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Loss Per
Share</b></font></td>
</tr>
</table>
<p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px">
<font style="FONT-FAMILY: Times New Roman" size="2">Basic net loss
per common share is computed by dividing the net loss available to
common stockholders by the weighted average number of common shares
outstanding during the period. Diluted net loss per common share is
computed by dividing the net loss available to common stockholders
by the weighted average number of common shares and other potential
common shares then outstanding. The computation of diluted net loss
per share does not assume the issuance of common shares that have
an anti-dilutive effect on net loss per share. Dilutive shares
which could exist pursuant to the exercise of outstanding stock
instruments and which were not included in the calculation because
their affect would have been anti-dilutive are as
follows:</font></p>
<p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">
 </p>
<table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center">
<tr>
<td width="74%"></td>
<td valign="bottom" width="3%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="3%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1">June 30, 2013<br />
(shares)</font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1">June 30, 2012<br />
(shares)</font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Warrants to purchase shares
of common stock</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,395,908</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">7,424,241</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
</tr>
<tr>
<td valign="top">
<p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Options to purchase shares
of common stock</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,552,840</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,291,630</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Shares of common stock
issuable upon conversion of preferred stock</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,618,772</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2,627,110</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td> </td>
</tr>
<tr>
<td valign="top"></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">13,567,520</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">13,342,981</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
</tr>
</table>
</div>
102594
109953
13567520
<div>
<p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px">
<font style="FONT-FAMILY: Times New Roman" size="2">Following is
the stock-based compensation expense related to common stock
options, common stock, restricted common stock and common stock
warrants:</font></p>
<p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">
 </p>
<table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center">
<tr>
<td width="74%"></td>
<td valign="bottom" width="3%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="3%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="3%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="3%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1">Three Months Ended</font><br />
<font style="FONT-FAMILY: Times New Roman" size="1">June 
30,</font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1">Six Months Ended</font><br />
<font style="FONT-FAMILY: Times New Roman" size="1">June 
30,</font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1">2013</font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1">2012</font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1">2013</font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1">2012</font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom" colspan="14" align="center"><font style="FONT-FAMILY: Times New Roman" size="1">(in thousands)</font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and
development</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">211</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">359</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">530</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">508</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
</tr>
<tr>
<td valign="top">
<p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">General and
administrative</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">404</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">520</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">937</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">844</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td> </td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Total stock-based
compensation expense</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">615</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">879</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,467</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,352</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
</tr>
</table>
</div>
<div>
<p style="margin-top:0px;margin-bottom:0px; text-indent:8%">
<font style="font-family:Times New Roman" size="2">The fair value
of all other options granted is determined using the Black-Scholes
option-pricing model. The following weighted average assumptions
were used:</font></p>
<p style="font-size:12px;margin-top:0px;margin-bottom:0px">
 </p>
<table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE" align="center">
<tr>
<td width="68%"></td>
<td valign="bottom" width="9%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="9%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1">Six Months Ended<br />
June 30,</font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center"><font style="font-family:Times New Roman" size="1">Cumulative<br />
Period from<br />
Inception<br />
(July 10, 2000) to<br />
June 30,</font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1">2013</font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1">2013</font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Risk-free interest
rate</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">0.97</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">% </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">1.75</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">% </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Expected life of the
options</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">5.5 years</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">5.2 years</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Expected volatility of the
underlying stock</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">116</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">% </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">119</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">% </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Expected dividend
rate</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">0</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">% </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">0</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">% </font></td>
</tr>
</table>
</div>
-0.94
2.57
225426
<div>
<table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="100%">
<tr>
<td valign="top" width="4%" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>3.</b></font></td>
<td valign="top" align="left"><font style="FONT-FAMILY: Times New Roman" size="2"><b>Stock-Based
Compensation</b></font></td>
</tr>
</table>
<p style="MARGIN-TOP: 6px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px">
<font style="FONT-FAMILY: Times New Roman" size="2">Following is
the stock-based compensation expense related to common stock
options, common stock, restricted common stock and common stock
warrants:</font></p>
<p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">
 </p>
<table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="92%" align="center">
<tr>
<td width="74%"></td>
<td valign="bottom" width="3%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="3%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="3%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="3%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1">Three Months Ended</font><br />
<font style="FONT-FAMILY: Times New Roman" size="1">June 
30,</font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="6" align="center"><font style="FONT-FAMILY: Times New Roman" size="1">Six Months Ended</font><br />
<font style="FONT-FAMILY: Times New Roman" size="1">June 
30,</font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1">2013</font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1">2012</font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1">2013</font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1">2012</font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom" colspan="14" align="center"><font style="FONT-FAMILY: Times New Roman" size="1">(in thousands)</font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Research and
development</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">211</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">359</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">530</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">508</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
</tr>
<tr>
<td valign="top">
<p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">General and
administrative</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">404</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">520</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">937</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">844</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td> </td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Total stock-based
compensation expense</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">615</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">879</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,467</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1,352</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
</tr>
</table>
<p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px">
<font style="FONT-FAMILY: Times New Roman" size="2">The following
table summarizes the stock option activity in the Company’s
equity incentive plans, including non-plan grants to Company
executives, from December 31, 2012 through June 30,
2013:</font></p>
<p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">
 </p>
<table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center">
<tr>
<td width="72%"></td>
<td valign="bottom" width="8%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="8%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1">Shares</font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1">Weighted Average<br />
Exercise Price</font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Outstanding,
December 31, 2012</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,539,961</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.66</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
</tr>
<tr>
<td valign="top">
<p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Granted</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">225,426</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3.42</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Exercised</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(102,594</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">2.57</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
</tr>
<tr>
<td valign="top">
<p style="TEXT-INDENT: -1em; MARGIN-LEFT: 3em"><font style="FONT-FAMILY: Times New Roman" size="2">Options
forfeited/cancelled</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">(109,953</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">) </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">6.40</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 1px solid"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Outstanding, June 30,
2013</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">3,552,840</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.58</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
</tr>
<tr style="FONT-SIZE: 1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td valign="bottom">
<p style="BORDER-TOP: #000000 3px double"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
</tr>
</table>
<p style="MARGIN-TOP: 12px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px">
<font style="FONT-FAMILY: Times New Roman" size="2">As of
June 30, 2013, there was $4,962,000 of unrecognized
compensation related to 1,315,137 unvested options, which is
expected to be recognized over a weighted–average period of
approximately 4.1 years. The weighted-average grant date fair value
for options granted during the three and six months ended
June 30, 2013 was $3.64 and $2.83, respectively. The
weighted-average grant date fair value for options granted during
the three and six months ended June 30, 2012 was
$1.72.</font></p>
<p style="MARGIN-TOP: 12px; MARGIN-BOTTOM: 0px; FONT-SIZE: 1px">
 </p>
<p style="MARGIN-TOP: 0px; TEXT-INDENT: 8%; MARGIN-BOTTOM: 0px">
<font style="FONT-FAMILY: Times New Roman" size="2">The fair value
of all other options granted is determined using the Black-Scholes
option-pricing model. The following weighted average assumptions
were used:</font></p>
<p style="MARGIN-TOP: 0px; MARGIN-BOTTOM: 0px; FONT-SIZE: 12px">
 </p>
<table style="BORDER-COLLAPSE: collapse" border="0" cellspacing="0" cellpadding="0" width="76%" align="center">
<tr>
<td width="68%"></td>
<td valign="bottom" width="9%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="9%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1">Six Months Ended<br />
June 30,</font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1">Cumulative<br />
Period from<br />
Inception<br />
(July 10, 2000) to<br />
June 30,</font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1">2013</font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td style="BORDER-BOTTOM: #000000 1px solid" valign="bottom" colspan="2" align="center"><font style="FONT-FAMILY: Times New Roman" size="1">2013</font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Risk-free interest
rate</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0.97</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">1.75</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td>
</tr>
<tr>
<td valign="top">
<p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Expected life of the
options</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.5 years</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">5.2 years</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">  </font></td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Expected volatility of the
underlying stock</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">116</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">119</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td>
</tr>
<tr>
<td valign="top">
<p style="TEXT-INDENT: -1em; MARGIN-LEFT: 1em"><font style="FONT-FAMILY: Times New Roman" size="2">Expected dividend
rate</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="FONT-FAMILY: Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="FONT-FAMILY: Times New Roman" size="2">0</font></td>
<td valign="bottom" nowrap="nowrap"><font style="FONT-FAMILY: Times New Roman" size="2">% </font></td>
</tr>
</table>
</div>
33333
5000
<div>
<table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%">
<tr>
<td width="4%" valign="top" align="left"><font style="font-family:Times New Roman" size="2"><b>8.</b></font></td>
<td align="left" valign="top"><font style="font-family:Times New Roman" size="2"><b>Commitments,
Contingencies and Legal Proceedings</b></font></td>
</tr>
</table>
<p style="margin-top:6px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2"><i>Agreement with CTI for
Phase I Clinical Trial</i></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%">
<font style="font-family:Times New Roman" size="2">On February
1, 2013, the Company entered into an Amended and Restated Master
Services Agreement (the “Agreement”) with CTI Clinical
Trial Services, Inc. and CTI Clinical Consulting Services,
Inc. (individually and collectively, “CTI”),
whereby CTI is assisting the Company in the design, development and
conduct of one or more clinical research studies from time to
time. All work performed by CTI for the Company is being
conducted pursuant to the terms of work orders that describe the
specific obligations undertaken by CTI with respect to any
particular clinical research study sponsored or conducted by the
Company. Unless otherwise terminated sooner in accordance with
the terms of the Agreement, the Agreement will be effective until
January 31, 2018.</font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%">
<font style="font-family:Times New Roman" size="2">On
February 1, 2013, the Company entered into a work order (the
“Work Order”) with CTI in accordance with the terms of
the Agreement. The Work Order provides that CTI will provide
services with respect to the Company’s Phase I Clinical Trial
to evaluate the safety of the Company’s drug GR-MD-02 in
subjects with Non-Alcoholic Steatohepatitis (“NASH”)
with advanced hepatic fibrosis. CTI is providing the following
services, amongst others, with respect to the Work Order:
reviewing and providing notices regarding IND safety reports,
selecting investigators and monitors for the study, informing
investigators of new observations, monitoring the progress of the
study and reviewing ongoing investigations, keeping certain
records, inspecting the Company’s records and reports, and
disposing of any unused supply of the investigational
drug.</font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%">
<font style="font-family:Times New Roman" size="2">The Work Order
provides for CTI’s anticipated involvement in the study from
February 1, 2013 until March 31, 2014. The estimated
budget for the Work Order is $2,155,000, which is subject to change
as necessary, with payments made throughout the term of the project
as the work is performed. During the three and six months ended
June 30, 2013, the Company recognized $361,000 and $1,090,000,
respectively, of expenses related to this agreement for services
performed.</font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%">
<font style="font-family:Times New Roman" size="2">The Agreement or
any work order may be terminated for any reason by any party upon
ninety (90) days prior written notice to the other party. In
addition, the Agreement may be terminated by either party
immediately if the other party becomes insolvent, is dissolved or
liquidated, makes a general assignment for the benefit of its
creditors, files or has filed against it (and does not obtain a
dismissal within ninety (90) days) a petition of bankruptcy,
or has a receiver appointed for it or a substantial part of its
assets, among other reasons. Further, the Agreement or any relevant
work order may be terminated immediately by written notice from the
Company, in the following circumstances: (1) the FDA withdraws
authorization and approval to conduct a study; or (2) the
Company reasonably determines that for medical, clinical or patient
safety reasons, a study should terminate immediately. In addition,
either party may terminate the Agreement or any work order for
material breach upon thirty (30) days’ written notice
specifying the nature of the breach, if such breach has not been
substantially cured within the thirty (30) day
period.</font></p>
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2"><i>Drug Discovery Program
with the University of Georgia</i></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%">
<font style="font-family:Times New Roman" size="2">In February
2013, the Company established a collaborative drug discovery
program at the Complex Carbohydrate Research Center at
the University of Georgia. This program is focused on the
discovery of new carbohydrate molecules that can be used in the
therapy of diseases where galectin proteins play a major role,
including cancer and inflammatory and fibrotic disorders. The term
of the agreement is effective through December 31, 2013, for
which the Company will provide funding of $154,000 during the
period as work is performed. The Company has paid $135,000 related
to this program through June 30, 2013. This agreement may be
terminated by either party upon 90 days notice.</font></p>
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2"><i>Separation
Agreement</i></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:8%">
<font style="font-family:Times New Roman" size="2">In February
2009, the Company entered into a Separation Agreement in connection
with the resignation of David Platt, Ph.D., the Company’s
former Chief Executive Officer and Chairman of the Board of
Directors. The Separation Agreement provides for the deferral of a
$1.0 million separation payment due to Dr. Platt upon the
earlier occurrence of any of the following milestone events:
(i) the approval by the Food and Drug Administration for a new
drug application (“NDA”) for any drug candidate or drug
delivery candidate based on the Company’s GM-CT-01 technology
(whether or not such technology is patented), in which case
Dr. Platt is also entitled to a fully vested 10-year
cashless-exercise stock option to purchase at least 83,334 shares
of common stock at an exercise price not less than the fair market
value of the common stock determined as of the date of grant;
(ii) consummation of a transaction with a pharmaceutical
company expected to result in at least $10.0 million of equity
investment or $50 million of royalty revenue to the Company, in
which case Dr. Platt is also entitled to stock options on the
same terms to purchase at least 50,000 shares of common stock; or
(iii) the renewed listing of the Company’s securities on
a national securities exchange and the achievement of a market
capitalization of $100 million. Payment upon the events
(i) and (iii) may be deferred up to six months, and if
the Company has insufficient cash at the time of any of such
events, it may issue Dr. Platt a secured promissory note for
such amount. If the Company files a voluntary or involuntary
petition for bankruptcy, whether or not a milestone event has
occurred, such event shall trigger the obligation to pay the $1.0
million with the result that Dr. Platt may assert a claim for
such obligation against the bankruptcy estate. During 2011, when it
became probable that the Company could be relisted on a national
securities exchange and eventually reach a market capitalization of
$100 million, the Company recognized the $1.0 million severance
payment due to Dr. Platt and it is included in accrued
expenses at June 30, 2013 and December 31,
2012.</font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:8%">
<font style="font-family:Times New Roman" size="2">On May 2,
2012, Dr. Platt instituted an arbitration with the American
Arbitration Association seeking the $1 million payment based on a
claim that the milestone event in the Separation Agreement
described in clause (iii) above had occurred. Although the
Company had listed its common stock on the Nasdaq Capital Markets
as of March 22, 2012, the market capitalization since the
listing had not reached $100 million when the arbitration was heard
in October 2012. On November 1, 2012, the arbitrator denied
Dr. Platt’s demand in all respects.</font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:8%">
<font style="font-family:Times New Roman" size="2">On
October 12, 2012, Dr. Platt commenced a lawsuit under the
Massachusetts Wage Act against Dr. Traber and
Mr. McGauley who in their capacities as the Company’s
Chief Executive Officer and Chief Financial Officer respectively
can be held individually liable under the Wage Act for non-payment
of wages. The lawsuit is based on the facts and issues raised in
the arbitration regarding the payment of the $1.0 million
separation payment under the Separation Agreement, and other
unspecified “wages”. The statute provides that a
successful claimant may be entitled to multiple damages, interest
and attorney’s fees. Although the Company is not a party to
the lawsuit, it plans to indemnify Dr. Traber and
Mr. McGauley consistent with its obligations under the by-laws
and applicable law, believes the lawsuit is without merit, and
intends a vigorous defense on their behalf. On April 29, 2013,
the Court allowed Dr. Traber’s and
Mr. McGauley’s motion to dismiss. Dr. Platt filed a
Notice of Appeal to appeal the Court’s order allowing the
defendants’ motion to dismiss.</font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:8%">
<font style="font-family:Times New Roman" size="2">On
March 29, 2013, the Company instituted arbitration before the
American Arbitration Association, seeking to rescind or reform the
Separation Agreement discussed above. The Company claims that
Dr. Platt fraudulently induced the Company to enter into the
Separation Agreement, breached his fiduciary duty to the Company,
and was unduly enriched from his conduct. Along with removal of the
$1.0 million milestone payment under the Separation Agreement, the
Company is seeking repayment of all separation benefits paid to
Dr. Platt to date. Depending on the outcome of the
arbitration, the previously accrued $1.0 million could be reversed.
The timing and ultimate outcome of this arbitration, though, is
uncertain and there is no guarantee that the Company will be
successful in this demand.</font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:13%">
<font style="font-family:Times New Roman" size="2">On
August 1, 2013, the market capitalization of the
Company’s common stock exceeded $100 million. As described in
the preceding paragraph, the Company had previously instituted an
arbitration against Dr. Platt seeking to rescind the
Separation Agreement, including the milestone payment
provision.</font></p>
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2"><i>Series C Post Conversion
Dividend Rights</i></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:8%">
<font style="font-family:Times New Roman" size="2">In January 2013,
5 shares of the Company’s Series C Super Dividend Convertible
Preferred Stock (“Series C”) were converted into 8,475
shares of common stock (consisting of 8,334 shares of common stock
for principal and 141 shares for accrued interest at the time of
the conversion) which also resulted in the issuance of 5 Series C
post-conversion dividend rights (“Dividend Rights”).
Under the terms of the Series C, the Dividend Rights entitle the
holder only to dividend payments based on actual sales of GM-CT-01
and will not participate in the 6% dividend payable on outstanding
shares of Series C following a conversion to common stock. At
June 30, 2013, there are a total of 10 outstanding Dividend
Rights which were determined to have a de minimis value, because
payment of a dividend for the Dividend Rights is considered
improbable at this time and the Company has not recorded a
liability related to the Dividend Rights. The Company will continue
to evaluate and assess the Dividend Rights for each reporting
period. At June 30, 2013, the Dividend Rights had a redemption
value of $241,000.</font></p>
<p style="margin-top:18px;margin-bottom:0px"><font style="font-family:Times New Roman" size="2"><i>Other Legal
Proceedings</i></font></p>
<p style="margin-top:6px;margin-bottom:0px; text-indent:8%">
<font style="font-family:Times New Roman" size="2">The Company
records accruals for such contingencies to the extent that the
Company concludes that their occurrence is probable and the related
damages are estimable, except as noted above. There has been no
change in the matters reported in our Annual Report on Form 10-K
for the year ended December 31, 2012.</font></p>
</div>
90000
8000
-15113000
-65000
-5755000
8000
-5747000
49000
1467000
2654000
90000
26000
1467000
6000
-4265000
5755000
490000
-1000
3101000
-145000
113000
8763000
2.65
<div>
<table style="BORDER-COLLAPSE:COLLAPSE" border="0" cellpadding="0" cellspacing="0" width="100%">
<tr>
<td width="4%" valign="top" align="left"><font style="font-family:Times New Roman" size="2"><b>7.</b></font></td>
<td align="left" valign="top"><font style="font-family:Times New Roman" size="2"><b>Common Stock and Warrant
Offering and Reverse Split</b></font></td>
</tr>
</table>
<p style="margin-top:6px;margin-bottom:0px; text-indent:4%">
<font style="font-family:Times New Roman" size="2">On
March 22, 2012, the Company entered into an underwriting
agreement relating to the offer and sale of 1,159,445 units (the
“Units”) of the Company. Each unit consisted of two
shares of Common Stock and one warrant to purchase one share of
Common Stock. Pursuant to the underwriting agreement, the Company
granted the underwriters a 45-day option to purchase up to an
additional 173,916 Units to cover over-allotments, which they
exercised on March 26, 2012. The public offering price for
each Unit was $9.00. Each warrant has an initial exercise price of
$5.63 per share, is exercisable upon separation of the Units and
expires on March 28, 2017.</font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%">
<font style="font-family:Times New Roman" size="2">On
March 28, 2012, the Company sold and issued 1,333,361 Units
(2,666,722 shares of common stock and related $5.63 warrants to
purchase 1,333,361 shares of common stock) for gross proceeds of
$12.0 million (net cash proceeds of $10,403,000 after the
underwriting discount and offering costs). The warrants were valued
at $4,445,000 as of the issuance date of March 28, 2012, using
the closing price of $4.20, a life of 5 years, a volatility of 119%
and a risk free interest rate of 1.05%. Based upon the
Company’s analysis of the criteria contained in ASC Topic
815-40, “Derivatives and Hedging—Contracts in
Entity’s Own Equity” the Company has determined that
warrants issued in connection with this financing transaction were
not derivative liabilities and therefore, were recorded as
additional paid-in capital.</font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%">
<font style="font-family:Times New Roman" size="2">On
March 28, 2012, in connection with this underwritten financing
as per the underwriting agreement, the Company issued a total of
46,378 common stock purchase warrants to the underwriters. These
warrants expire May 2, 2016, have an exercise price of $5.63
per share, and are exercisable beginning 1 year from March 22,
2012 (the date of the underwriting agreement). These warrants were
valued at $143,000 as of the date of issuance (March 28, 2012),
using the closing price of $4.20, life of 4.1 years, volatility of
117% and risk free interest rate of 0.78. Based upon the
Company’s analysis of the criteria contained in ASC Topic
815-40, “Derivatives and Hedging—Contracts in
Entity’s Own Equity”, the Company has determined that
these warrants issued in connection with this financing transaction
were not derivative liabilities and therefore, were recorded as
additional paid-in capital.</font></p>
<p style="margin-top:12px;margin-bottom:0px; text-indent:4%">
<font style="font-family:Times New Roman" size="2">Effective as of
March 23, 2012, and in connection with the pricing of the
offering of Units, the Company effected a one-for-six reverse split
of its Common Stock. Per the terms of the reverse split, all
fractional shares were rounded up.</font></p>
</div>
5000000
1090000
2018-01-31
3.00
<div>
<p style="margin-top:6px;margin-bottom:0px; text-indent:8%">
<font style="font-family:Times New Roman" size="2">The following
table summarizes the common stock warrant activity from
December 31, 2012 through June 30, 2013:</font></p>
<p style="font-size:12px;margin-top:0px;margin-bottom:0px">
 </p>
<table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE" align="center">
<tr>
<td width="72%"></td>
<td valign="bottom" width="8%"></td>
<td></td>
<td></td>
<td></td>
<td valign="bottom" width="8%"></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1">Shares</font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom" colspan="2" align="center" style="border-bottom:1px solid #000000"><font style="font-family:Times New Roman" size="1">Weighted Average<br />
Exercise Price</font></td>
<td valign="bottom"><font size="1"> </font></td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Outstanding,
December 31, 2012</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">7,424,241</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">3.71</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Granted</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">5,000</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">2.65</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Exercised</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">—  </font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">—  </font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr>
<td valign="top">
<p style="margin-left:3.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Forfeited/cancelled</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">(33,333</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">) </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">3.00</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:1px solid #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
</tr>
<tr bgcolor="#CCEEFF">
<td valign="top">
<p style="margin-left:1.00em; text-indent:-1.00em"><font style="font-family:Times New Roman" size="2">Outstanding, June 30,
2013</font></p>
</td>
<td valign="bottom"><font size="1">  </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2"> </font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">7,395,908</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
<td valign="bottom"><font size="1"> </font></td>
<td valign="bottom"><font style="font-family:Times New Roman" size="2">$</font></td>
<td valign="bottom" align="right"><font style="font-family:Times New Roman" size="2">3.74</font></td>
<td nowrap="nowrap" valign="bottom"><font style="font-family:Times New Roman" size="2">  </font></td>
</tr>
<tr style="font-size:1px">
<td valign="bottom"></td>
<td valign="bottom">  </td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td valign="bottom">
<p style="border-top:3px double #000000"> </p>
</td>
<td> </td>
<td valign="bottom"> </td>
<td valign="bottom"></td>
<td valign="bottom"></td>
<td valign="bottom"></td>
</tr>
</table>
</div>
87000
490000
90000
158000
8763000
1.13
0.0119
0.0074
1.22
0
P5Y9M11D
P7Y7D
0.77
0.0022
0.0011
0.96
0
P9M7D
P2Y4D
-5747000
26000
87000
8763000
62000
57000
260000
111000
90000
49000
1467000
-8763000
-62000
-57000
-260000
-111000
-5
-49000
8475
102594
17114
15625
66476
28490
-26000
-79000
-8000
937000
530000
3552840
2618772
7395908
7000
14360000
1.72
-3670000
13342981
-0.36
11000
-5188000
-19000
-4621000
11000
-4610000
2505000
10403000
1352000
4000
6733000
4621000
464000
10403000
2116000
-435000
114000
16000
4445000
464000
190000
844000
508000
3291630
2627110
7424241
1159445
173916
P45D
0.1667
1333361
10403000
2666722
12000000
1.17
0.0078
P4Y1M6D
4.20
143000
1.19
0.0105
P5Y
4.20
5.63
4445000
83334
50000000
P6M
P10Y
1000000
0.06
5
5
8475
8334
141
0.0042
0.87
P3Y
0.00
P90D
P30D
135000
P90D
1000000
P5Y
2429923
578553
0.0175
1.19
P5Y2M12D
0.00
-62908000
1641000
68800000
431000
12243000
404000
691000
826000
107000
-95385000
114000
91000
-80401000
2662000
-77739000
171000
9000
49690000
68842000
4279000
13841000
561000
5099000
80401000
4725000
10621000
351000
4451000
39093000
5000
-835000
30711000
1481000
-9022000
4158000
329000
9482000
4645000
11383000
832000
503000
-3426000
8763000
2203000
1691000
3935000
1548000
16236000
3.64
-0.72
P4Y1M6D
3000
-11641000
-2547000
3000
-2544000
1198000
615000
2547000
277000
1349000
57000
8763000
5000000
361000
8763000
1.13
0.0119
0.0074
1.22
0
P5Y9M11D
P7Y7D
0.77
0.0022
0.0011
0.96
0
P9M7D
P2Y4D
404000
211000
15710000
1.72
-0.19
8000
-2984000
-2668000
8000
-2660000
1453000
879000
2668000
267000
1215000
57000
520000
359000
0001133416
us-gaap:ResearchAndDevelopmentExpenseMember
2012-03-29
2012-06-30
0001133416
us-gaap:GeneralAndAdministrativeExpenseMember
2012-03-29
2012-06-30
0001133416
2012-03-29
2012-06-30
0001133416
us-gaap:ResearchAndDevelopmentExpenseMember
2013-04-01
2013-06-30
0001133416
us-gaap:GeneralAndAdministrativeExpenseMember
2013-04-01
2013-06-30
0001133416
us-gaap:MaximumMembergalt:BeforeModificationMember
2013-04-01
2013-06-30
0001133416
us-gaap:MinimumMembergalt:BeforeModificationMember
2013-04-01
2013-06-30
0001133416
galt:BeforeModificationMember
2013-04-01
2013-06-30
0001133416
us-gaap:MaximumMembergalt:AfterModificationMember
2013-04-01
2013-06-30
0001133416
us-gaap:MinimumMembergalt:AfterModificationMember
2013-04-01
2013-06-30
0001133416
galt:AfterModificationMember
2013-04-01
2013-06-30
0001133416
2013-04-01
2013-06-30
0001133416
galt:SeriesBOnePreferredStockMember
2000-07-11
2013-06-30
0001133416
galt:SeriesBTwoPreferredStockMember
2000-07-11
2013-06-30
0001133416
us-gaap:SeriesAPreferredStockMember
2000-07-11
2013-06-30
0001133416
us-gaap:SeriesCPreferredStockMember
2000-07-11
2013-06-30
0001133416
2000-07-11
2013-06-30
0001133416
us-gaap:SubsequentEventMember
2013-07-01
2013-08-14
0001133416
galt:ClassATwoWarrantsMember
2013-04-01
2013-05-06
0001133416
2012-05-01
2012-05-31
0001133416
galt:DrugDiscoveryProgramMember
2013-01-02
2013-02-01
0001133416
2013-01-02
2013-02-01
0001133416
us-gaap:WarrantMember
2013-01-01
2013-01-31
0001133416
galt:AccruedInterestMemberus-gaap:CommonStockMember
2013-01-01
2013-01-31
0001133416
galt:PrincipalSharesMemberus-gaap:CommonStockMember
2013-01-01
2013-01-31
0001133416
us-gaap:CommonStockMember
2013-01-01
2013-01-31
0001133416
us-gaap:SeriesCPreferredStockMember
2013-01-01
2013-01-31
0001133416
2013-01-01
2013-01-31
0001133416
2012-10-01
2012-10-31
0001133416
us-gaap:MinimumMember
2009-02-01
2009-02-28
0001133416
2009-02-01
2009-02-28
0001133416
galt:WarrantOneMember
2012-03-02
2012-03-28
0001133416
galt:WarrantTwoMember
2012-03-02
2012-03-28
0001133416
2012-03-02
2012-03-28
0001133416
2012-03-02
2012-03-23
0001133416
2012-03-02
2012-03-22
0001133416
us-gaap:WarrantMember
2012-01-01
2012-06-30
0001133416
us-gaap:StockCompensationPlanMember
2012-01-01
2012-06-30
0001133416
us-gaap:EmployeeStockOptionMember
2012-01-01
2012-06-30
0001133416
us-gaap:ResearchAndDevelopmentExpenseMember
2012-01-01
2012-06-30
0001133416
us-gaap:GeneralAndAdministrativeExpenseMember
2012-01-01
2012-06-30
0001133416
2012-01-01
2012-06-30
0001133416
us-gaap:WarrantMember
2013-01-01
2013-06-30
0001133416
us-gaap:WarrantMember
2013-01-01
2013-06-30
0001133416
us-gaap:StockCompensationPlanMember
2013-01-01
2013-06-30
0001133416
us-gaap:EmployeeStockOptionMember
2013-01-01
2013-06-30
0001133416
us-gaap:ResearchAndDevelopmentExpenseMember
2013-01-01
2013-06-30
0001133416
us-gaap:GeneralAndAdministrativeExpenseMember
2013-01-01
2013-06-30
0001133416
galt:SeriesBOnePreferredStockMember
2013-01-01
2013-06-30
0001133416
galt:SeriesBTwoPreferredStockMember
2013-01-01
2013-06-30
0001133416
galt:SeriesBOnePreferredStockMemberus-gaap:CommonStockMember
2013-01-01
2013-06-30
0001133416
galt:SeriesBTwoPreferredStockMemberus-gaap:CommonStockMember
2013-01-01
2013-06-30
0001133416
us-gaap:SeriesAPreferredStockMemberus-gaap:CommonStockMember
2013-01-01
2013-06-30
0001133416
us-gaap:SeriesCPreferredStockMemberus-gaap:CommonStockMember
2013-01-01
2013-06-30
0001133416
us-gaap:CommonStockMember
2013-01-01
2013-06-30
0001133416
us-gaap:SeriesCPreferredStockMember
2013-01-01
2013-06-30
0001133416
galt:SeriesBOnePreferredStockMemberus-gaap:AdditionalPaidInCapitalMember
2013-01-01
2013-06-30
0001133416
galt:SeriesBTwoPreferredStockMemberus-gaap:AdditionalPaidInCapitalMember
2013-01-01
2013-06-30
0001133416
us-gaap:SeriesAPreferredStockMemberus-gaap:AdditionalPaidInCapitalMember
2013-01-01
2013-06-30
0001133416
us-gaap:SeriesCPreferredStockMemberus-gaap:AdditionalPaidInCapitalMember
2013-01-01
2013-06-30
0001133416
us-gaap:AdditionalPaidInCapitalMember
2013-01-01
2013-06-30
0001133416
galt:SeriesBOnePreferredStockMemberus-gaap:AccumulatedDeficitDuringDevelopmentStageMember
2013-01-01
2013-06-30
0001133416
galt:SeriesBTwoPreferredStockMemberus-gaap:AccumulatedDeficitDuringDevelopmentStageMember
2013-01-01
2013-06-30
0001133416
us-gaap:SeriesAPreferredStockMemberus-gaap:AccumulatedDeficitDuringDevelopmentStageMember
2013-01-01
2013-06-30
0001133416
us-gaap:SeriesCPreferredStockMemberus-gaap:AccumulatedDeficitDuringDevelopmentStageMember
2013-01-01
2013-06-30
0001133416
us-gaap:AccumulatedDeficitDuringDevelopmentStageMember
2013-01-01
2013-06-30
0001133416
us-gaap:MaximumMembergalt:BeforeModificationMember
2013-01-01
2013-06-30
0001133416
us-gaap:MinimumMembergalt:BeforeModificationMember
2013-01-01
2013-06-30
0001133416
galt:BeforeModificationMember
2013-01-01
2013-06-30
0001133416
us-gaap:MaximumMembergalt:AfterModificationMember
2013-01-01
2013-06-30
0001133416
us-gaap:MinimumMembergalt:AfterModificationMember
2013-01-01
2013-06-30
0001133416
galt:AfterModificationMember
2013-01-01
2013-06-30
0001133416
2013-01-01
2013-06-30
0001133416
galt:SeriesBOnePreferredStockMember
2012-12-31
0001133416
galt:SeriesBTwoPreferredStockMember
2012-12-31
0001133416
us-gaap:SeriesCPreferredStockMember
2012-12-31
0001133416
us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember
2012-12-31
0001133416
galt:SeriesBOnePreferredStockMember
2012-12-31
0001133416
galt:SeriesBTwoPreferredStockMember
2012-12-31
0001133416
us-gaap:CommonStockMember
2012-12-31
0001133416
us-gaap:SeriesAPreferredStockMember
2012-12-31
0001133416
us-gaap:SeriesCPreferredStockMember
2012-12-31
0001133416
us-gaap:AdditionalPaidInCapitalMember
2012-12-31
0001133416
us-gaap:AccumulatedDeficitDuringDevelopmentStageMember
2012-12-31
0001133416
2012-12-31
0001133416
2011-12-31
0001133416
us-gaap:SubsequentEventMember
2013-08-31
0001133416
galt:SeriesBOnePreferredStockMember
2013-06-30
0001133416
galt:SeriesBTwoPreferredStockMember
2013-06-30
0001133416
us-gaap:SeriesCPreferredStockMember
2013-06-30
0001133416
us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember
2013-06-30
0001133416
galt:SeriesBOnePreferredStockMember
2013-06-30
0001133416
galt:SeriesBTwoPreferredStockMember
2013-06-30
0001133416
us-gaap:CommonStockMember
2013-06-30
0001133416
us-gaap:SeriesAPreferredStockMember
2013-06-30
0001133416
us-gaap:SeriesCPreferredStockMember
2013-06-30
0001133416
us-gaap:AdditionalPaidInCapitalMember
2013-06-30
0001133416
us-gaap:AccumulatedDeficitDuringDevelopmentStageMember
2013-06-30
0001133416
2013-06-30
0001133416
2012-06-30
0001133416
galt:WarrantOneMember
2012-03-28
0001133416
galt:WarrantTwoMember
2012-03-28
0001133416
2012-03-22
0001133416
2013-08-13
0001133416
galt:ClassBWarrantsMember
2013-05-06
0001133416
galt:ClassATwoWarrantsMember
2013-05-06
0001133416
galt:DrugDiscoveryProgramMember
2013-02-01
0001133416
2013-02-01
0001133416
us-gaap:WarrantMember
2013-01-31
0001133416
us-gaap:MinimumMember
2009-02-28
0001133416
2009-02-28
iso4217:USD
shares
iso4217:USD
galt:Right
iso4217:USD
shares
galt:Right
pure
galt:Warrants